The mechanism of resistance to favipiravir in influenza

Initiation, Elongation, and Realignment during Influenza Virus mRNA Synthesis

(2017) Aartjan J. W. te Velthuis et al.   JOURNAL OF VIROLOGY

Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase

(2017) Rana Abdelnabi et al.   JOURNAL OF VIROLOGY

Signatures of Nucleotide Analog Incorporation by an RNA-Dependent RNA Polymerase Revealed Using High-Throughput Magnetic Tweezers

(2017) David Dulin et al.   Cell Reports

A novel twelve class fluctuation test reveals higher than expected mutation rates for influenza A viruses

(2017) Matthew D Pauly et al.   eLife

Epistatic Interactions within the Influenza A Virus Polymerase Complex Mediate Mutagen Resistance and Replication Fidelity

(2017) Matthew D. Pauly et al.   mSphere

In VitroAssessment of Combinations of Enterovirus Inhibitors against Enterovirus 71

(2016) Yizhuo Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis

(2016) Evelien Vanderlinden et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir

(2016) Emi Takashita et al.   ANTIVIRAL RESEARCH

Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses

(2016) Jonna B. Westover et al.   ANTIVIRAL RESEARCH

Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice

(2016) Bindumadhav M. Marathe et al.   Scientific Reports

A Structural Overview of RNA-Dependent RNA Polymerases from the Flaviviridae Family

(2015) Jiqin Wu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever

(2015) Lisa Oestereich et al.   JOURNAL OF INFECTIOUS DISEASES

Effective Lethal Mutagenesis of Influenza Virus by Three Nucleoside Analogs

(2015) Matthew D. Pauly et al.   JOURNAL OF VIROLOGY

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

(2014) Lisa Oestereich et al.   ANTIVIRAL RESEARCH

Common and unique features of viral RNA-dependent polymerases

(2014) Aartjan J. W. te Velthuis   CELLULAR AND MOLECULAR LIFE SCIENCES

Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral

(2014) Leen Delang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of Susceptibility Variants of Influenza Virus Grown in the Presence of T-705

(2014) Tohru Daikoku et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Structure of influenza A polymerase bound to the viral RNA promoter

(2014) Alexander Pflug et al.   NATURE

Generation and characterization of influenza A viruses with altered polymerase fidelity

(2014) Peter P. H. Cheung et al.   Nature Communications

Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance

(2014) Stéphanie Beaucourt et al.   Current Opinion in Virology

The epidemiology and spread of drug resistant human influenza viruses

(2014) Aeron C Hurt   Current Opinion in Virology

Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase

(2013) Hidehiro Sangawa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro

(2013) T. Baranovich et al.   JOURNAL OF VIROLOGY

The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase

(2013) Zhinan Jin et al.   PLoS One

Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID

(2011) C. B. Jabara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses

(2010) K. Sleeman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance

(2010) J. D. Bloom et al.   SCIENCE

Population dynamics of an RNA virus and its defective interfering particles in passage cultures

(2010) Kristen Thompson et al.   Virology Journal

Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice

(2009) D. F. Smee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Evolution of Influenza Resistance and Treatment

(2009) David M. Weinstock   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

T-705 (favipiravir) activity against lethal H5N1 influenza A viruses

(2009) M. Kiso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?

(2008) Frederick Hayden   CLINICAL INFECTIOUS DISEASES